JP Morgan Chase’s GSK GSK Stock Holding History

JP Morgan Chase’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,840	Closed	-$343K	–	5452
2019 Q4	$343K	Hold	5,840	–	–	﹤0.01%	4432
2019 Q3	$312K	Buy	+5,840	New	+$300K	﹤0.01%	4404
2019 Q2	–	Sell	-2,880	Closed	-$150K	–	5847
2019 Q1	$150K	Buy	2,880 +480	+20%	+$24K	﹤0.01%	4738
2018 Q4	$115K	Buy	+2,400	New	+$118K	﹤0.01%	4793
2018 Q2	–	Sell	-1,920	Closed	-$94K	–	5588
2018 Q1	$94K	Buy	1,920 +240	+14%	+$11.2K	﹤0.01%	4607
2017 Q4	$74K	Buy	+1,680	New	+$77.6K	﹤0.01%	4770
2016 Q3	–	Sell	-84,000	Closed	-$4.55M	–	4643
2016 Q2	$4.55M	Buy	+84,000	New	+$4.43M	﹤0.01%	2360
2016 Q1	–	Sell	-80	Closed	-$4K	–	4780
2015 Q4	$4K	Hold	80	–	–	﹤0.01%	4388
2015 Q3	$4K	Hold	80	–	–	﹤0.01%	3877
2015 Q2	$4K	Sell	80 -7,760	-99%	-$437K	﹤0.01%	3985
2015 Q1	$452K	Buy	7,840 +5,573	+246%	+$319K	﹤0.01%	3575
2014 Q4	$121K	Buy	+2,267	New	+$127K	﹤0.01%	4085
2014 Q1	–	Sell	-80	Closed	-$5K	–	3714
2013 Q4	$5K	Hold	80	–	–	﹤0.01%	4055
2013 Q3	$5K	Hold	80	–	–	﹤0.01%	4344
2013 Q2	$5K	Buy	+80	New	+$5.08K	﹤0.01%	4352

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase's GSK Position: Q1 2026 in Review

JP Morgan Chase reduced its GSK (GSK) stake by 75% in Q1 2026, selling an estimated $92.3M and leaving 578,828 shares worth $31.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

JP Morgan Chase first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $536M in Q3 2015. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

JP Morgan Chase held 578,828 shares of GSK worth $31.4M as of Q1 2026.
JP Morgan Chase sold 1,702,989 GSK shares in Q1 2026, an estimated $92.3M.
GSK made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1703 holding.
JP Morgan Chase first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's GSK position peaked at $536M in Q3 2015.
1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.